{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:39:55Z","timestamp":1784774395128,"version":"3.55.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["#K08 CA270385"],"award-info":[{"award-number":["#K08 CA270385"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.suc.2024.02.014","type":"journal-article","created":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:13:45Z","timestamp":1711185225000},"page":"863-881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Management of Pheochromocytomas and Paragangliomas"],"prefix":"10.1016","volume":"104","author":[{"given":"Jesse E.","family":"Passman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wachtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.suc.2024.02.014_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"9486","key":"10.1016\/j.suc.2024.02.014_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.suc.2024.02.014_bib3","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1210\/jc.2009-1632","article-title":"Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas","volume":"95","author":"Van Duinen","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.suc.2024.02.014_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"9","key":"10.1016\/j.suc.2024.02.014_bib7","doi-asserted-by":"crossref","first-page":"bvac105","DOI":"10.1210\/jendso\/bvac105","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"Journal of the Endocrine Society"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib8","doi-asserted-by":"crossref","first-page":"e2251","DOI":"10.1210\/clinem\/dgaa965","article-title":"Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study","volume":"106","author":"Ebbehoj","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.suc.2024.02.014_bib9","first-page":"1","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms","volume":"15","author":"Soltani","year":"2016","journal-title":"J\u00a0Diabetes Metab Disord"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib10","first-page":"637","article-title":"A\u00a0survey on adrenal incidentaloma in Italy","volume":"85","author":"Mantero","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1210\/er.2002-0031","article-title":"The clinically inapparent adrenal mass: update in diagnosis and management","volume":"25","author":"Mansmann","year":"2004","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1651-2227.1992.tb12213.x","article-title":"A\u00a0single pediatric center experience with 1025 children with hypertension","volume":"81","author":"Wyszy\u0144ska","year":"1992","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib13","first-page":"691","article-title":"Pathophysiology and diagnosis of disorders of the adrenal medulla: focus on pheochromocytoma","volume":"4","author":"Lenders","year":"2011","journal-title":"Compr Physiol"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib14","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1210\/jc.2004-1398","article-title":"Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma","volume":"90","author":"Amar","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib15","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pgen.0010008","article-title":"A\u00a0HIF1\u03b1 regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"05","key":"10.1016\/j.suc.2024.02.014_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2265.1998.3751208.x","article-title":"Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma","volume":"48","author":"Pomares","year":"1998","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib19","first-page":"659","article-title":"Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma","volume":"162","author":"WALTHER","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MED.0000000000000634","article-title":"Genetics of pheochromocytoma and paraganglioma","volume":"28","author":"Wachtel","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","article-title":"Update on modern management of pheochromocytoma and paraganglioma","volume":"32","author":"Lenders","year":"2017","journal-title":"Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.hoc.2015.09.006","article-title":"Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment","volume":"30","author":"Fishbein","year":"2016","journal-title":"Hematol\/Oncol Clin"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib24","first-page":"1582","article-title":"von Recklinghausen\u2032 s disease and pheochromocytomAS","volume":"162","author":"Walther","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.amjmed.2012.07.022","article-title":"Pheochromocytoma and gastrointestinal stromal tumors in patients with neurofibromatosis type I","volume":"126","author":"Vlenterie","year":"2013","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib27","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.maturitas.2013.12.009","article-title":"Pheochromocytoma: a review","volume":"77","author":"Tsirlin","year":"2014","journal-title":"Maturitas"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib28","doi-asserted-by":"crossref","first-page":"E1223","DOI":"10.1152\/ajpendo.90591.2008","article-title":"Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma","volume":"295","author":"Eisenhofer","year":"2008","journal-title":"Am J Physiol Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ijsu.2014.04.001","article-title":"Current concepts of pheochromocytoma","volume":"12","author":"Conzo","year":"2014","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib31","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-19-0435","article-title":"Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop","volume":"27","author":"Dahia","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.suc.2024.02.014_bib32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1245\/s10434-013-2942-5","article-title":"Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing","volume":"20","author":"Fishbein","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.suc.2024.02.014_bib33","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.suc.2024.02.014_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s003450050102","article-title":"Pheochromocytoma: evaluation, diagnosis, and treatment","volume":"17","author":"Walther","year":"1999","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1210\/jc.2012-3669","article-title":"Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines?","volume":"98","author":"Stolk","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"05","key":"10.1016\/j.suc.2024.02.014_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0032-1306294","article-title":"High incidence of cardiovascular complications in pheochromocytoma","volume":"44","author":"Zelinka","year":"2012","journal-title":"Horm Metab Res"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib37","doi-asserted-by":"crossref","first-page":"R135","DOI":"10.1530\/EJE-16-0189","article-title":"Management of endocrine disease: recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"175","author":"Amar","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1210\/clinem\/dgaa794","article-title":"Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy: a systematic review and meta-analysis","volume":"106","author":"Holscher","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1677\/ERC-07-0074","article-title":"The diagnosis and management of malignant phaeochromocytoma and paraganglioma","volume":"14","author":"Chrisoulidou","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol"},{"issue":"05","key":"10.1016\/j.suc.2024.02.014_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0031-1299707","article-title":"Metastatic pheochromocytoma and paraganglioma: focus on therapeutics","volume":"44","author":"Plouin","year":"2012","journal-title":"Horm Metab Res"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib42","doi-asserted-by":"crossref","first-page":"L51","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.suc.2024.02.014_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1022981801344","article-title":"Pheochromocytoma as an endocrine emergency","volume":"4","author":"Brouwers","year":"2003","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.suc.2024.02.014_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1245\/s10434-014-3933-x","article-title":"Clinicopathologic characteristics of incidentally identified pheochromocytoma","volume":"22","author":"Wachtel","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib46","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib47","first-page":"863","article-title":"Multiple endocrine neoplasia syndromes","volume":"88","author":"Callender","year":"2008","journal-title":"Surg Clin"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0039-6257(01)00245-4","article-title":"von Hippel\u2013Lindau disease","volume":"46","author":"Singh","year":"2001","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/oxfordjournals.aje.a113947","article-title":"Biochemical screening for pheochromocytoma: superiority of urinary metanephrines measurements","volume":"120","author":"MANU","year":"1984","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7326\/0003-4819-123-2-199507150-00004","article-title":"Plasma metanephrines in the diagnosis of pheochromocytoma","volume":"123","author":"Lenders","year":"1995","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.suc.2024.02.014_bib51","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2265.2007.02805.x","article-title":"The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma","volume":"66","author":"Perry","year":"2007","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib53","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical Assessment of Pheochromocytoma and Paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib54","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2967\/jnumed.120.259689","article-title":"Imaging of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"16","key":"10.1016\/j.suc.2024.02.014_bib55","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.suc.2024.02.014_bib56","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.surg.2009.09.013","article-title":"Biopsy of pheochromocytomas and paragangliomas: potential for disaster","volume":"146","author":"Vanderveen","year":"2009","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.suc.2024.02.014_bib57","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41436-020-0921-3","article-title":"Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma\u2013pheochromocytoma syndrome","volume":"22","author":"Greenberg","year":"2020","journal-title":"Genet Med"},{"issue":"02","key":"10.1016\/j.suc.2024.02.014_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-0032-1331217","article-title":"Mortality associated with phaeochromocytoma","volume":"45","author":"Prejbisz","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.suc.2024.02.014_bib59","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00268-002-6667-z","article-title":"Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma","volume":"26","author":"Prys-Roberts","year":"2002","journal-title":"World J Surg"},{"issue":"11","key":"10.1016\/j.suc.2024.02.014_bib60","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Preoperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"key":"10.1016\/j.suc.2024.02.014_bib61","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00268-005-0373-6","article-title":"Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients","volume":"30","author":"Walz","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.suc.2024.02.014_bib62","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00423-011-0879-3","article-title":"Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series","volume":"397","author":"Agarwal","year":"2012","journal-title":"Langenbeck's Arch Surg"},{"issue":"9","key":"10.1016\/j.suc.2024.02.014_bib63","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archsurg.2010.159","article-title":"One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy","volume":"145","author":"Shen","year":"2010","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/gs.2019.10.20","article-title":"Surgical approach to patients with pheochromocytoma","volume":"9","author":"Patel","year":"2020","journal-title":"Gland Surg"},{"issue":"3","key":"10.1016\/j.suc.2024.02.014_bib65","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.surg.2011.07.004","article-title":"Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma","volume":"150","author":"Dickson","year":"2011","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib66","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.surg.2019.03.034","article-title":"Patient selection and outcomes of laparoscopic transabdominal versus posterior retroperitoneal adrenalectomy among surgeons in the Collaborative Endocrine Surgery Quality Improvement Program (CESQIP)","volume":"167","author":"Marrero","year":"2020","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.suc.2024.02.014_bib67","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/bjs.8921","article-title":"Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy","volume":"99","author":"Constantinides","year":"2012","journal-title":"Journal of British Surgery"},{"issue":"6","key":"10.1016\/j.suc.2024.02.014_bib68","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.surg.2003.08.005","article-title":"Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy","volume":"134","author":"Brauckhoff","year":"2003","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib69","doi-asserted-by":"crossref","first-page":"e198898","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-8587(20)30363-6","article-title":"Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature","volume":"9","author":"Bancos","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.suc.2024.02.014_bib71","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.surg.2014.08.020","article-title":"Hypoglycemia after resection of pheochromocytoma","volume":"156","author":"Chen","year":"2014","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib72","doi-asserted-by":"crossref","first-page":"101347","DOI":"10.1016\/j.beem.2019.101347","article-title":"Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies","volume":"34","author":"Schreiner","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib73","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jamcollsurg.2012.10.012","article-title":"Long-term outcomes of surgical treatment for hereditary pheochromocytoma","volume":"216","author":"Grubbs","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"12","key":"10.1016\/j.suc.2024.02.014_bib74","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/archsurg.141.12.1199","article-title":"Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A","volume":"141","author":"Asari","year":"2006","journal-title":"Arch Surg"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib75","first-page":"1855","article-title":"Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup","volume":"184","author":"Benhammou","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.suc.2024.02.014_bib76","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas\u2014A meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib78","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.suc.2024.02.014_bib79","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.jvir.2009.07.031","article-title":"Radiofrequency ablation of metastatic pheochromocytoma","volume":"20","author":"Venkatesan","year":"2009","journal-title":"J\u00a0Vasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.suc.2024.02.014_bib80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/cancers11020195","article-title":"Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma","volume":"11","author":"Kohlenberg","year":"2019","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.suc.2024.02.014_bib81","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jvir.2011.06.016","article-title":"Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy","volume":"22","author":"McBride","year":"2011","journal-title":"J\u00a0Vasc Intervent Radiol"},{"key":"10.1016\/j.suc.2024.02.014_bib82","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fonc.2014.00166","article-title":"External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma","volume":"4","author":"Vogel","year":"2014","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","article-title":"External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma","volume":"3","author":"Breen","year":"2018","journal-title":"Advances in Radiation Oncology"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib84","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"Van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib85","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.suc.2024.02.014_bib86","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.suc.2024.02.014_bib87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib88","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.MLG.0000165806.99675.A9","article-title":"Are somatostatin analogs therapeutic alternatives in the management of head and neck paragangliomas?","volume":"115","author":"Duet","year":"2005","journal-title":"Laryngoscope"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib89","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin Endocrinol"},{"issue":"7","key":"10.1016\/j.suc.2024.02.014_bib90","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.suc.2024.02.014_bib91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"11","key":"10.1016\/j.suc.2024.02.014_bib92","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.suc.2024.02.014_bib93","series-title":"Clinical presentation and outcomes in patients with advanced pheochromcytoma\/paraganglioma: evidence of temozolomide efficacy","author":"Halperin","year":"2014"},{"key":"10.1016\/j.suc.2024.02.014_bib94","series-title":"A phase 2 open-Label study of belzutifan (a HIF-2 [alpha] inhibitor) monotherapy in patients with advanced\/metastatic pheochromocytoma\/paraganglioma or pancreatic neuroendocrine tumors","author":"Jimenez","year":"2023"},{"issue":"22","key":"10.1016\/j.suc.2024.02.014_bib95","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.suc.2024.02.014_bib96","series-title":"A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma","author":"Del Rivero","year":"2023"},{"issue":"8","key":"10.1016\/j.suc.2024.02.014_bib97","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924000306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924000306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T06:34:55Z","timestamp":1719556495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610924000306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0039610924000306"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2024.02.014","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Pheochromocytomas and Paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2024.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}